Lilly experimental 'triple G' obesity drug leads to 24.2% weight loss in trial

(Reuters) -Eli Lilly on Monday said a mid-stage trial of its next-generation obesity drug candidate “triple G” showed that it led to weight loss of up to 24.2% after 48 weeks, surpassing results seen with other weight loss drugs. Read full story

Source : https://www.thestar.com.my/news/world/2023/06/27/lilly-experimental-039triple-g039-obesity-drug-leads-to-242-weight-loss-in-trial